A Phase I Study of JS108 in Patients With Advanced Solid Tumors

Summary

This is a phase I, open-label, first-in-human clinical study designed to evaluate the safety, tolerability, PK profile and efficacy of JS108 for patients with advanced solid tumors. This study is divided into 3 periods: dose escalation period, dose expansion period, and clinical expansion period.

Timeline

Start

2020-10-28

Primary completion

2023-06-14

Completion

2023-06-14

Outcome

Outcome not reported

Stopped: “Sponsor has adjusted study development plan and terminated this clinical study.”

Drugs

Indications